Skip to content

Study · Animal study (in vivo) · mouse · 2024

12 results

Kisspeptins centrally modulate food intake and locomotor activity in mice independently of gonadal steroids in a sexually dimorphic manner.

Velasco I, Daza-Dueñas S, Torres E, Ruiz-Pino F, Vázquez MJ, Tena-Sempere M

Journal of neuroendocrinology23 Jul 2024Cited by 1 (Europe PMC)

PMID39041546 (opens in a new tab)DOI10.1111/jne.13433 (opens in a new tab)PepBankPUB-39041546
Publisher pagePubMedAsk about this study
Jump to 12 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study12

12 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In male mice, central Kp-10 decreased food intake, especially during the dark phase.

    In plain wordsIn male mice, kisspeptin‑10 given into the brain lowered food intake, mainly at night.

    Peptide
    Kisspeptin-10
    Outcome
    DecreaseFood intake, central Kp-10, male mice
    Study

    mousen: not reported in source

    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    1 nmol daily · central · 11 daysAs given in this study (mouse).

    Measurements

    Food intake decrease, dark phase
    ≈ 50%
    male mice, central

    Source sentences

    Summary
    Central administration of Kp-10 decreased food intake in male mice, especially during the dark phase (~50%), which was accompanied by a reduction in total and nocturnal energy expenditure (~16%) and locomotor activity (~70%).
    1 context sentence
    Summary · context
    We present herein a series of studies addressing the metabolic effects of central and peripheral administration of kisspeptin-10 (Kp-10; 1 nmol and 3 nmol daily, respectively) for 11 days in mice of both sexes.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In male mice, central Kp-10 reduced total and nocturnal energy expenditure.

    In plain wordsIn male mice, kisspeptin‑10 given into the brain lowered energy use.

    Peptide
    Kisspeptin-10
    Outcome
    DecreaseEnergy expenditure, central Kp-10, male mice
    Study

    mousen: not reported in source

    Outcome group
    Energy expenditure and thermogenesis · Metabolic and weight
    Studied dose
    1 nmol daily · central · 11 daysAs given in this study (mouse).

    Measurements

    Energy expenditure reduction
    ≈ 16%
    male mice, central

    Source sentences

    Summary
    Central administration of Kp-10 decreased food intake in male mice, especially during the dark phase (~50%), which was accompanied by a reduction in total and nocturnal energy expenditure (~16%) and locomotor activity (~70%).
    1 context sentence
    Summary · context
    We present herein a series of studies addressing the metabolic effects of central and peripheral administration of kisspeptin-10 (Kp-10; 1 nmol and 3 nmol daily, respectively) for 11 days in mice of both sexes.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In male mice, central Kp-10 reduced locomotor activity.

    In plain wordsIn male mice, kisspeptin‑10 given into the brain made them move less.

    Peptide
    Kisspeptin-10
    Outcome
    DecreaseLocomotor activity, central Kp-10, male mice
    Study

    mousen: not reported in source

    Outcome group
    Locomotor and behavioral activity · Nervous system and cognition
    Studied dose
    1 nmol daily · central · 11 daysAs given in this study (mouse).

    Measurements

    Locomotor activity reduction
    ≈ 70%
    male mice, central

    Source sentences

    Summary
    Central administration of Kp-10 decreased food intake in male mice, especially during the dark phase (~50%), which was accompanied by a reduction in total and nocturnal energy expenditure (~16%) and locomotor activity (~70%).
    1 context sentence
    Summary · context
    We present herein a series of studies addressing the metabolic effects of central and peripheral administration of kisspeptin-10 (Kp-10; 1 nmol and 3 nmol daily, respectively) for 11 days in mice of both sexes.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In female mice, central Kp-10 increased total and nocturnal locomotor activity.

    In plain wordsIn female mice, kisspeptin‑10 given into the brain made them move more.

    Peptide
    Kisspeptin-10
    Outcome
    IncreaseLocomotor activity, central Kp-10, female mice
    Study

    mousen: not reported in source

    Outcome group
    Locomotor and behavioral activity · Nervous system and cognition
    Studied dose
    1 nmol daily · central · 11 daysAs given in this study (mouse).

    Measurements

    Locomotor activity increase
    > 65%
    female mice, central

    Source sentences

    Summary
    In contrast, opposite patterns were detected in female mice, with an increase in total and nocturnal locomotor activity (>65%), despite no changes in food intake or energy expenditure.
    1 context sentence
    Summary · context
    We present herein a series of studies addressing the metabolic effects of central and peripheral administration of kisspeptin-10 (Kp-10; 1 nmol and 3 nmol daily, respectively) for 11 days in mice of both sexes.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In female mice, central Kp-10 did not change food intake.

    In plain wordsIn female mice, kisspeptin‑10 given into the brain did not change food intake.

    Peptide
    Kisspeptin-10
    Outcome
    No significant changeFood intake, central Kp-10, female mice
    Study

    mousen: not reported in source

    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    1 nmol daily · central · 11 daysAs given in this study (mouse).

    Source sentences

    Summary
    In contrast, opposite patterns were detected in female mice, with an increase in total and nocturnal locomotor activity (>65%), despite no changes in food intake or energy expenditure.
    1 context sentence
    Summary · context
    We present herein a series of studies addressing the metabolic effects of central and peripheral administration of kisspeptin-10 (Kp-10; 1 nmol and 3 nmol daily, respectively) for 11 days in mice of both sexes.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In female mice, central Kp-10 did not change energy expenditure.

    In plain wordsIn female mice, kisspeptin‑10 given into the brain did not change energy use.

    Peptide
    Kisspeptin-10
    Outcome
    No significant changeEnergy expenditure, central Kp-10, female mice
    Study

    mousen: not reported in source

    Outcome group
    Energy expenditure and thermogenesis · Metabolic and weight
    Studied dose
    1 nmol daily · central · 11 daysAs given in this study (mouse).

    Source sentences

    Summary
    In contrast, opposite patterns were detected in female mice, with an increase in total and nocturnal locomotor activity (>65%), despite no changes in food intake or energy expenditure.
    1 context sentence
    Summary · context
    We present herein a series of studies addressing the metabolic effects of central and peripheral administration of kisspeptin-10 (Kp-10; 1 nmol and 3 nmol daily, respectively) for 11 days in mice of both sexes.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In mice of both sexes, Kp-10 treatment caused no differences in body weight at the end of treatment.

    In plain wordsIn mice of both sexes, kisspeptin‑10 did not change body weight by the end of treatment.

    Peptide
    Kisspeptin-10
    Outcome
    No significant changeBody weight at end of Kp-10 treatment
    Study

    mousen: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    1 nmol and 3 nmol daily · central and peripheral · 11 daysAs given in this study (mouse).

    Source sentences

    Summary
    These changes were independent of body weight, as no differences were detected in mice of both sexes at the end of Kp-10 treatments.
    1 context sentence
    Summary · context
    We present herein a series of studies addressing the metabolic effects of central and peripheral administration of kisspeptin-10 (Kp-10; 1 nmol and 3 nmol daily, respectively) for 11 days in mice of both sexes.
  8. 08AnimalAnimal study (in vivo)Efficacy outcome

    In male mice, peripheral Kp-10 decreased locomotor activity.

    In plain wordsIn male mice, kisspeptin‑10 given outside the brain made them move less.

    Peptide
    Kisspeptin-10
    Outcome
    DecreaseLocomotor activity, peripheral Kp-10, male mice
    Study

    mousen: not reported in source

    Outcome group
    Locomotor and behavioral activity · Nervous system and cognition
    Studied dose
    3 nmol daily · peripheral · 11 daysAs given in this study (mouse).

    Source sentences

    Summary
    Peripheral administration of Kp-10 failed to alter any of the metabolic parameters analyzed, except for a decrease in locomotor activity in male mice and a subtle increase in 24 h food intake in female mice, denoting a predominant central role of kisspeptins in the control of energy metabolism.
    1 context sentence
    Summary · context
    We present herein a series of studies addressing the metabolic effects of central and peripheral administration of kisspeptin-10 (Kp-10; 1 nmol and 3 nmol daily, respectively) for 11 days in mice of both sexes.
  9. 09AnimalAnimal study (in vivo)Efficacy outcome

    In female mice, peripheral Kp-10 caused a subtle increase in 24 h food intake.

    In plain wordsIn female mice, kisspeptin‑10 given outside the brain slightly raised food intake over 24 hours.

    Peptide
    Kisspeptin-10
    Outcome
    Increase24 h food intake, peripheral Kp-10, female mice
    Study

    mousen: not reported in source

    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    3 nmol daily · peripheral · 11 daysAs given in this study (mouse).

    Source sentences

    Summary
    Peripheral administration of Kp-10 failed to alter any of the metabolic parameters analyzed, except for a decrease in locomotor activity in male mice and a subtle increase in 24 h food intake in female mice, denoting a predominant central role of kisspeptins in the control of energy metabolism.
    1 context sentence
    Summary · context
    We present herein a series of studies addressing the metabolic effects of central and peripheral administration of kisspeptin-10 (Kp-10; 1 nmol and 3 nmol daily, respectively) for 11 days in mice of both sexes.
  10. 10AnimalAnimal study (in vivo)Efficacy outcome

    In mice, peripheral Kp-10 did not alter the other metabolic parameters analysed.

    In plain wordsIn mice, kisspeptin‑10 given outside the brain did not change the other metabolic measures.

    Peptide
    Kisspeptin-10
    Outcome
    No significant changeOther metabolic parameters, peripheral Kp-10
    Study

    mousen: not reported in source

    Outcome group
    Energy expenditure and thermogenesis · Metabolic and weight
    Studied dose
    3 nmol daily · peripheral · 11 daysAs given in this study (mouse).

    Source sentences

    Summary
    Peripheral administration of Kp-10 failed to alter any of the metabolic parameters analyzed, except for a decrease in locomotor activity in male mice and a subtle increase in 24 h food intake in female mice, denoting a predominant central role of kisspeptins in the control of energy metabolism.
    1 context sentence
    Summary · context
    We present herein a series of studies addressing the metabolic effects of central and peripheral administration of kisspeptin-10 (Kp-10; 1 nmol and 3 nmol daily, respectively) for 11 days in mice of both sexes.
  11. 11AnimalAnimal study (in vivo)Efficacy outcome

    In mice, central or peripheral Kp-10 did not significantly affect glucose tolerance.

    In plain wordsIn mice, kisspeptin‑10 did not significantly change glucose tolerance.

    Peptide
    Kisspeptin-10
    Outcome
    No significant changeGlucose tolerance
    Study

    mousen: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1 nmol and 3 nmol daily · central and peripheral · 11 daysAs given in this study (mouse).

    Source sentences

    Summary
    Finally, glucose tolerance and insulin sensitivity were not significantly affected by central or peripheral treatment with Kp-10.
    1 context sentence
    Summary · context
    We present herein a series of studies addressing the metabolic effects of central and peripheral administration of kisspeptin-10 (Kp-10; 1 nmol and 3 nmol daily, respectively) for 11 days in mice of both sexes.
  12. 12AnimalAnimal study (in vivo)Efficacy outcome

    In mice, central or peripheral Kp-10 did not significantly affect insulin sensitivity.

    In plain wordsIn mice, kisspeptin‑10 did not significantly change insulin sensitivity.

    Peptide
    Kisspeptin-10
    Outcome
    No significant changeInsulin sensitivity
    Study

    mousen: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1 nmol and 3 nmol daily · central and peripheral · 11 daysAs given in this study (mouse).

    Source sentences

    Summary
    Finally, glucose tolerance and insulin sensitivity were not significantly affected by central or peripheral treatment with Kp-10.
    1 context sentence
    Summary · context
    We present herein a series of studies addressing the metabolic effects of central and peripheral administration of kisspeptin-10 (Kp-10; 1 nmol and 3 nmol daily, respectively) for 11 days in mice of both sexes.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 09:43 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.